MetaVia reports 9.1% weight loss in Phase 1 trial as clinical pipeline advances
MetaVia (NASDAQ:MTVA), a clinical-stage biopharmaceutical company developing novel therapies for obesity and metabolic-associated steatohepatitis (MASH), today reported financial results for the full year ended December 31, 2025, and provided an update on its advancing clinical pipeline.











